Lung Cancer News

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, offers advice to new residents seeing patients with EGFR-mutated lung cancer.

J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, spoke with Healio about monitoring patients with recurrent EGFR-mutated lung cancer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights important takeaways for interventional pulmonologists and other providers who may see patients with EGFR-mutated lung cancer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights potential treatments options coming to the EGFR-mutated lung cancer space.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, discusses the changing treatment landscape in EGFR-mutated lung cancer.

Patients with cancer who received immune checkpoint inhibitors exhibited increased risk for psoriasis compared with those treated with chemotherapy or targeted therapy.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

Most people at high risk for lung cancer have not discussed screening for the disease with their clinician or have even heard of the test, according to a research letter published in JAMA Network Open.

In this edition, single-fraction SBRT outcomes for central lung tumors, adjuvant durvalumab extends survival in limited-stage small cell lung cancer and more.